Stock FLGT FULGENT GENETICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Fulgent Genetics, Inc.

Equities

FLGT

US3596641098

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
21.39 USD +1.18% Intraday chart for Fulgent Genetics, Inc. -3.26% -26.01%
May. 03 Transcript : Fulgent Genetics, Inc., Q1 2024 Earnings Call, May 03, 2024
May. 03 Earnings Flash (FLGT) FULGENT GENETICS Posts Q1 Revenue $64.5M MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

1st Jan change Capi. Investor Rating ESG Refinitiv
FULGENT GENETICS, INC. Stock Fulgent Genetics, Inc.
-26.01% 633M
C-
SONIC HEALTHCARE LIMITED Stock Sonic Healthcare Limited
-23.07% 8.1B
B+
RADNET, INC. Stock RadNet, Inc.
+68.36% 4.26B
C+
DR. LAL PATHLABS LIMITED Stock Dr. Lal PathLabs Limited
+1.88% 2.57B
B-
SYNLAB AG Stock SYNLAB AG
-8.06% 2.49B -
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD. Stock Guangzhou Kingmed Diagnostics Group Co., Ltd.
-41.95% 2.39B
B-
NEOGENOMICS, INC. Stock NeoGenomics, Inc.
-11.99% 1.77B
C-
FLEURY S.A. Stock Fleury S.A.
-21.18% 1.53B
A-
METROPOLIS HEALTHCARE LIMITED Stock Metropolis Healthcare Limited
+17.44% 1.2B
B+
DIAN DIAGNOSTICS GROUP CO.,LTD. Stock Dian Diagnostics Group Co.,Ltd.
-43.89% 1.18B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. FLGT Stock
  4. Ratings Fulgent Genetics, Inc.